What are the benefits of albiglutide (Tanzeum) in the treatment of type 2 diabetes mellitus (DM)?

Updated: Sep 27, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

The glucagonlike peptide-1 (GLP-1) receptor agonist albiglutide (Tanzeum) was approved by the FDA in April 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [211, 212] GLP-1 agonists augment glucose-dependent insulin secretion. Approval of albiglutide was based on a series of individual phase III trials (Harmony 1-8) that included approximately 5,000 individuals.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!